B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.
Stocks · News reference
MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 Diabetes
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from
Macrogenics Q2 EPS $(0.31) Misses $0.02 Estimate, Sales $32.832M Miss $67.456M Estimate
8-K filing — MACROGENICS INC (MGNX)
Filed: 2026-08-13 AccNo: 0001125345-26-000054 Size: 353 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
Eli Lilly announced a definitive agreement to acquire clinical-stage biotech Merida Biosciences for up to $2.875 billion in an all-cash transaction. The deal adds MER511 for Graves' disease and thyroid eye disease, along with preclinical candidates for allergy and kidney disease. This acquisition marks Lilly's 10th major deal in 2026 as the company diversifies its pipeline beyond cardiometabolic medicines, leveraging strong cash generation from its blockbuster GLP-1 drugs.